Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane.

There was a reduction in perfusion following treatment in two out of six patients ( Figure 2 ), but this did not reach statistical significance (mean difference=0.09, P =0.15).

also in 111,027 other papers